Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

NCT07317609 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Tislelizumab
DRUG: Carboplatin
DRUG: Nab-paclitaxel
PROCEDURE: Endoscopic resection
PROCEDURE: Esophagectomy
RADIATION: Concurrent chemoradiation

Sponsor

Shanghai Zhongshan Hospital